在全球化能力建设方面，公司启动全球化战略，推进全球化的注册及临床开发能力建设。到2030年，公 司计划透过「海外授权+商业化」的双引擎驱动增长，加快国际化发展步伐。 格隆汇2月6日丨云顶新耀(01952.HK)宣布，中国国家药品监督管理局(NMPA)已批准维适平®(精氨酸艾 曲莫德片,VELSIPITY®)的新药上市申请(「新药上市申请」)，在中国用于治疗对传统治疗或生物制剂 应答不充分、失应答或不耐受的中度至重度活动性溃疡性结肠炎("UC")成人患者。 在疾病领域，公司聚焦肾科、自身免疫、急重症、心血管及眼科等核心方向，通过引进创新资产与自主 研发并行推进，到2030年形成高价值产品组合，并拓展其他蓝海领域的大单品。 在商业化平台建设上，公司已布局三款商业化产品，并着力建立全渠道商业化体系及药品全生命周期商 业化能力。公司计划到2028年实现收入规模超过100亿元人民币，而到2030年收入规模超过150亿元人民 币(其中现有管线销售收入约90亿元人民币而新引进管线销售收入约60亿元人民币)；收入的年复合增长 率预计在2025至2030年超过50%，2030年後保持超过15%。同时，商业化产品数量将提升至20 ...

Core Insights - The article highlights the recognition of CloudTop New Health for its innovative strategies and achievements in the biopharmaceutical industry, winning multiple awards for its performance in drug development and commercialization [1][3]. Group 1: Awards and Recognition - CloudTop New Health received the "Annual Outstanding Innovative Pharmaceutical Newcomer" and "Annual Outstanding Drug Research and Development Innovation Enterprise" awards at the 2025 21st Century Health Industry Competitiveness Research [1]. - The company was also listed among the "Top 40 Leading Enterprises in China's Innovative Drug Export" at the 2025 Singapore Business and Charity Forum, showcasing its strengths in independent research and international clinical advancement [1]. Group 2: Product Performance - The product Renfukang® achieved sales revenue of 303 million yuan in the first half of 2025, marking an 81% year-on-year increase, with total sales expected to reach 1.2 to 1.4 billion yuan for the full year [3]. - The antibiotic product Yijia® generated sales of 143 million yuan in the first half of 2025, reflecting a 6% increase, with a significant 37% growth in sales to core hospitals [4]. Group 3: Strategic Developments - CloudTop New Health's 2030 strategy emphasizes a "BD cooperation + self-research" dual-driven approach to enhance its global presence and innovation capabilities [7]. - The company plans to expand its product pipeline to over 20 commercialized products by 2030, including Renfukang®, Weishiping®, Yijia®, and others, targeting a revenue scale exceeding 15 billion yuan [9]. Group 4: Future Outlook - The company anticipates a compound annual growth rate of over 50% from 2025 to 2030, with a goal to maintain growth rates above 15% post-2030 [9]. - CloudTop New Health aims to maximize commercial value through diverse methods, including independent research and licensing, while accelerating the global rollout of its innovative drugs [9].

Core Insights - The company, CloudTop New Horizon, has established a solid foundation over the past eight years through license-in strategies and aims to become a leading global biopharmaceutical company by 2030 with a revenue target of over 15 billion RMB and more than 20 commercialized products [1][2][10] Group 1: Strategic Development - The 2030 development strategy focuses on a dual approach of business development (BD) cooperation and independent research and development, targeting a revenue of over 15 billion RMB and over 20 commercialized products by 2030 [1][2][10] - The company plans to introduce 3-5 late-stage blockbuster products annually over the next five years, enhancing its product pipeline [3][10] - The strategic partnerships with Haisen Biopharmaceuticals will provide commercialization services for six approved products, generating service fees based on quarterly net sales [3][4] Group 2: Product Pipeline and Market Focus - The company will focus on key therapeutic areas such as nephrology, autoimmune diseases, critical care, cardiovascular, and ophthalmology, aiming to create a high-value product portfolio by 2030 [2][10] - The revenue from existing pipelines is projected to be around 9 billion RMB, with new pipeline sales expected to contribute approximately 6 billion RMB [2] - The company has successfully commercialized the drug Nefukang, which has rapidly gained market traction, demonstrating its commercial capabilities [7][10] Group 3: Research and Development - CloudTop New Horizon is advancing its self-developed mRNA platforms, including CAR-T and tumor vaccine platforms, with ongoing clinical trials [8][9] - The company plans to expand its R&D capabilities by introducing and incubating potential platforms, aiming to strengthen its core therapeutic areas [9][10] - The new reversible BTK inhibitor EVER001 has shown promising clinical data, indicating a steady global R&D progress [9] Group 4: Commercialization Strategy - The company is leveraging its integrated commercialization platform, which combines scientific and market insights, to enhance its operational efficiency and productivity [4][8] - The collaboration with Haisen Biopharmaceuticals exemplifies the company's ability to extend its commercialization capabilities to mature products [8] - The company aims to transition from a biotech firm to a comprehensive biopharmaceutical company with global competitiveness, reflecting a broader trend in the Chinese innovative drug industry [8][10]

Core Insights - The company, CloudTop New Medicine (1952.HK), has officially launched its 2030 development strategy aimed at becoming a leading global biopharmaceutical company within the next five years [1][3] - The strategy emphasizes a dual approach of "BD collaboration + self-research" to drive growth and value creation [1][4] Financial Projections - By 2030, the company plans to achieve revenue exceeding 15 billion RMB, with approximately 9 billion RMB from existing pipeline sales and around 6 billion RMB from newly introduced pipeline sales [1] - The expected compound annual growth rate (CAGR) from 2025 to 2030 is projected to exceed 50% [1] Product Pipeline and Focus Areas - The company will focus on key therapeutic areas including nephrology, autoimmune diseases, critical care, cardiovascular, and ophthalmology [1][4] - The goal is to commercialize over 20 products by 2030, including existing products like Nefukang®, Weishiping®, and others [1] R&D and Platform Development - The company aims to expand its mRNA platform to include in vivo CAR-T and mRNA tumor vaccine platforms, as well as siRNA and antibody platforms by 2030 [2] - Plans include building a commercialization system in Europe, the US, and emerging markets to drive growth through "overseas licensing + commercialization" [2] Strategic Partnerships - As the largest shareholder of NewBridge Bio (holding approximately 16%), the company plans to deepen collaboration with NewBridge to leverage its global resources and expertise [2] Management Insights - The board emphasizes that the 2030 strategy marks a significant milestone towards becoming a global leader in biopharmaceuticals [4] - The company plans to introduce 3-5 late-stage products annually and aims to accumulate over 20 high-value assets by 2030 [4] Commercialization and Market Strategy - The company has established a commercial system driven by integrated insights across medical, access, market, and sales [5] - The sales of Nefukang® surpassed 1 billion RMB in the first three quarters, showcasing the company's effective commercialization capabilities [5] Shareholder Confidence - On December 12, key executives and board members collectively purchased 846,659 shares, amounting to over 38 million HKD, reflecting strong confidence in the company's future [5] - Major shareholder Kangqiao Capital has committed to increasing its stake by up to 1% in the next three to six months, subject to market conditions [5]

Core Insights - The company, CloudTop New Medicine, held a strategic investor meeting on October 21, where the new chairman, Wu Yifang, outlined the company's strategic direction focusing on key initiatives such as strategic transactions, R&D innovation, and stakeholder management [1] - The controlling shareholder, Kangqiao Capital, will not reduce its stake in the company in the short term [1] - The company aims to enhance its product pipeline through self-research, licensing, acquisitions, and capital empowerment, with a goal to maximize commercial value and expand globally [1] Product Pipeline and Financial Projections - CloudTop New Medicine's product pipeline in key therapeutic areas such as nephrology, infectious diseases, and autoimmune diseases is entering a critical harvest period [1] - The company estimates that sales for its product, Naisankang®, will reach between RMB 1.2 billion and RMB 1.4 billion for the year, with a target of RMB 2.4 billion to RMB 2.6 billion by 2026 [1] - The product Weishiping® (Aicuo Mod) is expected to become the next significant product for the company [1] Future Plans and Collaborations - The company plans to introduce more than three heavyweight products in the next 6 to 12 months, with potential domestic sales peak exceeding RMB 10 billion, aiming for an overall domestic sales peak of over RMB 20 billion [2] - CloudTop New Medicine has signed a cooperation development letter of intent with I-Mab for the treatment of retinal diseases, which will strengthen collaboration in innovative R&D and international development [2] - The global anti-VEGF ophthalmic drug market is projected to reach approximately USD 40 billion by 2030, indicating significant growth potential in this sector [2]

Core Insights - The company, CloudTop New Drug (01952.HK), held a strategic investor communication meeting on October 21, 2023, to discuss its latest strategic planning, R&D progress, and long-term development blueprint [1] Group 1: Leadership and Strategic Direction - The new chairman, Wu Yifang, will lead the board in setting the strategic direction and providing guidance to the executive team, focusing on strategic transactions, R&D innovation, and stakeholder management [2] - The major shareholder, Kangqiao Capital, has expressed confidence in the company's strategic outlook and will not reduce its stake in the short term, enhancing shareholder structure stability [2] Group 2: Strategic Focus and Market Expansion - The company will implement a "dual-engine" strategy, focusing on self-research and external collaborations to enrich its product pipeline and maximize commercial value [3] - CloudTop New Drug aims to accelerate its global expansion and self-research initiatives, particularly in key therapeutic areas such as nephrology, infectious diseases, and autoimmune diseases [3] Group 3: Product Pipeline and Financial Projections - The company’s products, including Nefukang® and Yijia®, have shown sustainable commercialization capabilities, with Nefukang® expected to achieve sales of approximately RMB 12 to 14 billion in 2025, and projected to grow to RMB 24 to 26 billion by 2026 [3] - The company plans to introduce over three significant products in the next 6 to 12 months, with potential domestic sales peak exceeding RMB 100 billion, aiming for an overall domestic sales peak of over RMB 200 billion [4] Group 4: R&D Innovations and Collaborations - The company is leveraging its mRNA cancer vaccine platform and CAR-T technology to establish a strong R&D foundation, with plans to enter high-growth areas such as ophthalmology [4] - A collaboration with I-Mab on the innovative product VIS-101 aims to enhance the company's presence in the ophthalmology market, which is projected to grow significantly [5][6] - VIS-101 has shown promising results in initial studies and is expected to enter Phase III trials by 2026, indicating a strong potential for market entry [5][6] Group 5: Overall Market Position and Future Outlook - The meeting highlighted the company's systematic progress in capital empowerment, innovation breakthroughs, and global expansion, reinforcing its competitiveness in the global innovative drug sector [6] - As core pipelines enter the value realization phase, the company is on a steady path toward becoming a leading comprehensive biopharmaceutical enterprise globally [6]

Core Insights - The company, CloudTop New Medicine (01952), held a strategic investor meeting on October 21, 2023, to discuss its latest strategic planning, R&D progress, and long-term development blueprint [1] Group 1: Leadership and Strategic Direction - The new chairman, Wu Yifang, will lead the board in setting the strategic direction and providing guidance to the management team, focusing on strategic transactions, R&D innovation, and stakeholder management [2] - The major shareholder, Kangqiao Capital, has expressed confidence in the company's strategic outlook and will not reduce its stake in the short term, which stabilizes the shareholder structure [2] Group 2: Dual-Engine Strategy and Market Expansion - The company will implement a "dual-engine" strategy, focusing on both in-house R&D and external collaborations, acquisitions, and capital empowerment to maximize commercial value [3] - Key therapeutic areas include nephrology, infectious diseases, and autoimmune diseases, with products like Nefukang® and Yijia® showing sustainable commercialization capabilities [3] - Nefukang® is projected to achieve sales of approximately RMB 1 billion in the first nine months of 2025, with an annual forecast of RMB 1.2 to 1.4 billion and a target of RMB 2.4 to 2.6 billion by 2026 [3] Group 3: R&D Advancements - The company is leveraging its mRNA cancer vaccine platform and autologous CAR-T platform to strengthen its R&D capabilities and explore high-growth areas like ophthalmology [4] - The new generation covalent reversible BTK inhibitor, EVER001, has shown promising clinical results and is set to enter pivotal trials in 2026 [4] - The company plans to introduce over three significant products in the next 6 to 12 months, with potential domestic sales peaks exceeding RMB 10 billion [4] Group 4: Strategic Collaboration with I-Mab - CloudTop New Medicine has signed a collaboration agreement with I-Mab for the development of VIS-101, a dual-specificity biologic for retinal diseases, enhancing its portfolio in the ophthalmology sector [5][6] - The global anti-VEGF ophthalmic drug market is projected to reach approximately $23 billion in 2024 and exceed $40 billion by 2030, indicating significant growth potential for innovative therapies [5][6] - The collaboration aims to accelerate the development of VIS-101 in the Asia-Pacific and the U.S., enhancing R&D efficiency and global expansion [6]

Core Viewpoint - The company, CloudTop New Medicine (1952.HK), reported strong mid-year performance for the period ending June 30, 2025, showcasing significant growth in both commercialization and R&D efforts, laying a solid foundation for becoming a leading global Biopharma company [1] Financial Performance - Total revenue for the first half of 2025 reached RMB 446 million, a substantial increase of 48% year-on-year [1] - Operating expenses as a percentage of revenue decreased by 40.1 percentage points, indicating improved operational efficiency [1] - Non-IFRS total loss narrowed significantly by 31%, with a gross margin of 76.4% after excluding non-cash items [1] - The company has a strong cash reserve of RMB 1.6 billion, bolstered by a recent fundraising of HKD 1.553 billion [1] Product Performance - The kidney disease treatment product, Nefukang®, saw impressive sales of RMB 303 million in the first half, an increase of 81% year-on-year [2] - Cumulative sales from January to August reached RMB 825 million, with August alone generating RMB 520 million [2] - The global first fluoroquinolone antibiotic, Yijia®, also showed steady growth with revenue of RMB 143 million, a 6% increase year-on-year [2] Strategic Initiatives - The company is advancing its "dual-wheel drive" strategy, focusing on high-potential products and enhancing its R&D capabilities [3] - The personalized tumor therapeutic vaccine EVM16 has initiated its first human clinical trial in China, with positive preliminary data [3] - The CAR-T project EVM18 is expected to start clinical trials by the end of 2025, with significant progress in its global R&D pipeline [4] Future Outlook - The company aims to achieve annual sales of RMB 1.6 to 1.8 billion and expects to reach operational profitability in the second half of 2025 [1][2] - The strategic focus will remain on the commercialization of Nefukang® and Weishiping®, alongside leveraging AI and mRNA technology platforms for early-stage R&D [5] - The company is targeting a peak sales potential exceeding RMB 25 billion in the future [5]

Core Viewpoint - The company, Cloudtop New Horizon (01952.HK), reported a significant revenue increase of RMB 144.6 million or 48.0% to RMB 446.1 million for the six months ending June 30, 2025, primarily driven by the growth of its commercialized products, NAI Fukan® and Yijia® [1] Revenue Growth - Revenue growth is attributed to the inclusion of NAI Fukan® in the national medical insurance drug list, which has become a major growth driver [1] - Yijia® continues to deepen its market penetration, contributing to sustained revenue growth [1] - NAI Fukan® successfully launched in Taiwan, marking a significant milestone for the company [1] - The introduction of Weishiping® into the Singapore market in the first half of 2025 highlights the company's progress in expanding international markets and improving drug accessibility [1] Research and Development - R&D expenditure decreased from RMB 253.2 million for the six months ending June 30, 2024, to RMB 195.2 million for the same period in 2025, reflecting strategic resource optimization and a focus on core pipeline breakthroughs [1] - The company achieved multiple R&D milestones in the first half of the year while actively optimizing its R&D strategy [1] - The company is accelerating the development of autologous CAR-T and mRNA platforms to prepare for the next phase of research and clinical trials, while continuing to develop the value of EVER001 (Civorebrutinib) [1]

Core Insights - The company reported a revenue of 446 million yuan for the six months ending June 30, 2025, representing a year-on-year increase of 47.96% [1] - Gross profit reached 299 million yuan, up 29.56% compared to the previous year [1] - The loss attributable to shareholders narrowed to 250 million yuan, a reduction of 60.5% year-on-year [1] Revenue Growth Drivers - Revenue growth was primarily driven by the continued market expansion of Naisukan® and Yijia® in commercialized markets [1] - In the Chinese market, Naisukan® was included in the national medical insurance drug list, significantly boosting its revenue for the six months ending June 30, 2025 [1] - Yijia®'s market penetration continued to deepen, contributing to sustained revenue growth [1] International Market Expansion - Naisukan® successfully launched in Taiwan, marking a significant milestone for the company [1] - In the international market, Weishiping® was successfully introduced to the Singapore market in the first half of 2025 [1] - These achievements highlight the company's progress in expanding international markets and improving drug accessibility [1]